8RP Stock Overview
An integrated pharmaceutical company, engages in the research, manufacture, and marketing of pharmaceutical products and preparations. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Celon Pharma S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł5.48 |
| 52 Week High | zł7.14 |
| 52 Week Low | zł3.23 |
| Beta | 0.82 |
| 1 Month Change | -5.35% |
| 3 Month Change | -6.16% |
| 1 Year Change | 62.37% |
| 3 Year Change | -9.27% |
| 5 Year Change | n/a |
| Change since IPO | -44.31% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8RP | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 1.3% | -3.6% | 2.1% |
| 1Y | 62.4% | -15.9% | 16.5% |
Return vs Industry: 8RP exceeded the German Pharmaceuticals industry which returned -14.6% over the past year.
Return vs Market: 8RP exceeded the German Market which returned 16.7% over the past year.
Price Volatility
| 8RP volatility | |
|---|---|
| 8RP Average Weekly Movement | 5.3% |
| Pharmaceuticals Industry Average Movement | 4.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 8RP has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 8RP's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 562 | Maciej Wieczorek | www.celonpharma.com |
Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of pharmaceutical products and preparations. It offers drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. The company was founded in 2002 and is based in Lomianki, Poland.
Celon Pharma S.A. Fundamentals Summary
| 8RP fundamental statistics | |
|---|---|
| Market cap | €312.39m |
| Earnings (TTM) | €4.45m |
| Revenue (TTM) | €50.33m |
70.3x
P/E Ratio6.2x
P/S RatioIs 8RP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8RP income statement (TTM) | |
|---|---|
| Revenue | zł209.54m |
| Cost of Revenue | zł64.10m |
| Gross Profit | zł145.43m |
| Other Expenses | zł126.92m |
| Earnings | zł18.51m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Apr 16, 2025
| Earnings per share (EPS) | 0.34 |
| Gross Margin | 69.41% |
| Net Profit Margin | 8.83% |
| Debt/Equity Ratio | 0% |
How did 8RP perform over the long term?
See historical performance and comparisonDividends
0.3%
Current Dividend Yield23%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/12 17:08 |
| End of Day Share Price | 2025/02/12 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Celon Pharma S.A. is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kamil Kliszcz | Biuro maklerskie mBanku |
| Beata Szparaga-Wasniewska | Biuro maklerskie mBanku |
| Vladimira Urbankova | Erste Group Bank AG |